Soleno Therapeutics, Inc (SLNO)

Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Recommends COVID-19 ...

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy. Details of the presentations are as follows: 2022 European Congress of Endocrinology (ECE) Title:DCCR UpdateFormat:Presentation at the I

KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL. The presentation will be available on-demand beginning at 7 AM Eastern

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2022. First Quarter 2022 and Recent Corporate Highlights Continuing dialogue with the U.S. Food and Drug Administration (FDA) to obtain alignment on the design of a study to provid

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients Presentations at the Pediatric Academic Societies 2022 Virtual Annual Meeting and Pediatric Endocrinology Society 2022 Virtual Annual Meeting REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced two presentations hig

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Another day of investing awaits for traders as we start it off with a breakdown of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

It started with hearing a podcast about Duchenne muscular dystrophy and progressed through an 11th grade biology class project. Now Shivin Kumar and Malyka Ram's Uplands Med is starting experiments at a San Carlos incubator.

A small Redwood City company's drug was working in a late-stage clinical trial in a devastating genetic disease that causes overeating. Then it didn't. A key researcher and the company blame a change in eating habits brought on by Covid.

Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) stock rose 35.1% to $1.73 during Wednesday's after-market session. At the close, HTG ...

REDWOOD CITY, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of an underwritten public offering of 40,000,000 shares of its common stock at a public offering price of $0.25 per share and, for certain investors, in lieu of common stock, pre-funded warrants to purchase 20,000,000 shares of its common stock at a publi

REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021. Fourth Quarter 2021 and Recent Corporate Highlights Received official meeting minutes on January 20, 2022, from the December 21, 2021, Type C meeting with

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM ...

Gainers IGM Biosciences (NASDAQ:IGMS) shares rose 114.8% to $32.2 during Tuesday's regular session. IGM ...

Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: ...

On Tuesday, 81 stocks hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Grupo Aval Acciones ...

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The ...

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of an underwritten public offering of 40,000,000 shares of its common stock at a public offering price of $0.25 per share and, for certain investors, in lieu of common stock, pre-funded warrants to purchase 20,000,000 shares of its common stock at a publi

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time to start another busy day of trading with another breakdown of the biggest pre-market stock movers on Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

REDWOOD CITY, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering and, in lieu of common stock, Soleno intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. Each share of common stock

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their ...

On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week ...